sclerostin monoclonal antibody

A sclerostin monoclonal antibody (Scl-mAb) is a therapeutic agent designed to target and inhibit sclerostin, a glycoprotein primarily secreted by osteocytes that acts as a negative regulator of bone formation. By binding to sclerostin, the antibody prevents it from interacting with low-density lipoprotein receptor-related protein 5 and 6 (LRP5/6) co-receptors, thereby restoring canonical Wnt/β-catenin signaling. This leads to a dual effect: stimulating osteoblast activity to promote bone formation and reducing osteoclast activity to inhibit bone resorption. Sclerostin monoclonal antibodies, such as the FDA-approved romosozumab, are primarily developed for the treatment of severe osteoporosis and other bone-related disorders characterized by low bone mass and high fracture risk.

Other names

Scl-mAbSOST antibodyanti-SOST antibodyanti-SOST monoclonal antibodyanti-sclerostin antibodyanti-sclerostin monoclonal antibodysclerostin antibody